Cutaneous Metastasis Of Breast Carcinoma Research Articles

Pigmented cutaneous metastasis of breast carcinoma: florid case with zosteriform distribution

Pigmented cutaneous metastasis of breast carcinoma: florid case with zosteriform distribution

Cutaneous metastasis of breast carcinoma on forearm-Classic FNAC finding

Cutaneous metastasis from internal malignancies are significant from diagnostic point of view considering their variable clinical presentation. Although, carcinoma breast is a common primary cancer in females producing skin metastasis, it is rather an uncommon site as common metastatic sites include lymph node, bone, lung, liver etc. Here we present a case of cutaneous metastasis in a 54 years old female who presented with complaints of a nodular swelling for three years. The skin over the swelling showed discoloration. Patient was a known case of carcinoma breast for which she had been operated on and had received treatment eight years back. FNAC done from the swelling showed typical metastatic foci of infiltrating duct carcinoma. The case is being reported in view of its classical cytological picture and its uncommon site of presentation. Keywords: FNAC, Cutaneous metastasis, Infiltrating Duct Carcinoma(IDC), Cytology.

A clinical, pathological and immunohistochemical series of 9 cases of primary cutaneous apocrine carcinomas of the head and neck.

Primary cutaneous apocrine carcinoma is a rare malignant adnexal skin tumour that can recur locally, spread to regional lymph nodes and metastatize to visceral organs. Wide dissemination and death from disease are much less common. The axilla is the most common site of presentation. It is infrequently reported in the head and neck region. All cases diagnosed as primary cutaneous apocrine carcinoma of the head and neck were retrospectively collected from the archives of the Division of Pathological Anatomy, University of Florence from 1996 to 2016. There was no history or clinical evidence of breast cancer. Clinical data and follow-up were collected by the clinicians. Nine cases were found, with a mean age of 76years, ranging in size between 0.3 and 3.5cm. Clinically, they were frequently mistaken for basal cell carcinomas. Histopathologically, all the tumours showed decapitation secretion, a tubular, solid or mixed (tubulo-papillary and solid-tubular) growth pattern and were predominantly classified as grade 2 tumours. GCDFP-15 and hormone receptors were variably expressed. HER2 and podoplanin were negative in all cases. In one case, spreading to regional lymph nodes was observed. No cases were associated with death due to the disease. As immunohistochemical analysis lacks specificity in distinguishing primary cutaneous apocrine carcinoma from a cutaneous metastasis of breast carcinoma, detailed clinical history, breast examination, adequate treatment and follow-up are necessary to confirm a diagnosis of primary cutaneous apocrine carcinoma.

Differential MicroRNA Landscape Triggered by Estrogens in Cancer Associated Fibroblasts (CAFs) of Primary and Metastatic Breast Tumors

Cancer associated fibroblasts (CAFs) play a main role in breast cancer progression and metastasis. Estrogens modulate in breast CAFs the expression of microRNAs (miRNAs) that are involved in the development of many tumors. In order to provide novel insights on the regulation of miRNAs by estrogens in breast cancer, we analyzed the expression of 754 miRNAs in CAFs obtained from primary mammary tumors and CAFs derived from a cutaneous breast cancer metastasis. Using the TaqMan™ Human MicroRNA Array, we found that 17β-estradiol (E2) modulates numerous peculiar and common miRNAs in CAFs derived from primary and the metastatic malignancies. In particular, we assessed that E2 modulates 133 miRNAs (41 up and 92 downregulated) in CAFs derived from primary breast tumors, whereas E2 modulates 415 miRNAs (399 up and 16 downregulated) in CAFs derived from a cutaneous metastasis of breast carcinoma. Therefore, a number of miRNAs three times higher in metastatic CAFs with respect to primary breast CAFs was found modulated by E2. Our findings shed new light on the cumulative regulation of miRNAs by E2 in the main players of the tumor microenvironment as CAFs. Moreover, our data may be taken into consideration that is useful toward innovative prognostic and therapeutic approaches in breast cancer progression.

Carcinoma en cuirasse with Zosteriform Metastasis-A Rare Presentation of Breast Carcinoma

Carcinoma en cuirasse is a form of cutaneous metastasis of breast carcinoma. Although a rare condition, it is most commonly associated with breast carcinoma with local recurrence after mastectomy and metastasis occurs a few months to years after primary has been diagnosed. Less frequently a metastasis is diagnosed at the same time as primary tumour is diagnosed. We report a case of carcinoma en cuirasse in a 60 year old female who presented with elevated nodular indurated skin lesions on anterior and posterior left chest wall and axillary region. FNAC of lesions was performed. It was diagnosed as metastatic deposits of Duct Cell Carcinoma. It was followed by histopathology and the diagnosis was confirmed. Hence it is very important to investigate thoroughly keloid like or indurated patches on skin of long duration.

Zosteriform cutaneous metastasis of breast carcinoma in a male patient

Zosteriform cutaneous metastasis of breast carcinoma in a male patient

How to differentiate mucinous eccrine carcinoma from cutaneous metastasis of breast carcinoma?

Eccrine skin tumors are rare and represent only 0,05% of all cutaneaous neoplasms. They represent a pitfall especially with cutaneous metastases of carcinoma which are more frequent. We report the case of a 60-year-old woman presented with a frontal scalp mass whose histologic and immunohistochemical features concluded initially to a cutaneous metastasis of breast carcinoma. The diagnosis was reviewed because of the absence of a breast lesion. The final diagnosis was primary sweet gland carcinoma. Histologic distinction between cutaneous metastatic breast carcinoma and primary cutaneous adnexal neoplasms can be very challenging or even impossible. This case illustrates this difficulty and puts emphasis on the necessity of keeping in mind the distinctive features between these two entities.

Primary apocrine carcinoma of scalp: Report of primary scalp cutaneous apocrine carcinoma indistinguishable from cutaneous metastasis of breast carcinoma

Cutaneous apocrine carcinoma (CAC) is a rare adnexal tumor. Its histological diagnosis criteria are not standardized, and it is difficult to distinguish apocrine carcinoma from metastasis of breast carcinoma. We report the case of a 60-year-old woman who suffered from scalp apocrine carcinoma that was first misdiagnosed as a cutaneous metastasis from breast adenocarcinoma.

An Immunohistochemical Panel to Differentiate Metastatic Breast Carcinoma to Skin From Primary Sweat Gland Carcinomas With a Review of the Literature

Approximately 25% of patients with breast cancer develop cutaneous metastases. Sweat gland carcinomas (SGCs) account for about 0.05% of all cutaneous neoplasms. Cutaneous metastases of breast carcinoma (CMBCs) (especially the ductal type) can be difficult to distinguish from SGCs. Treatment and prognoses for these 2 types of tumors differ radically, making accurate histologic diagnosis crucial. Although a few studies attempt to differentiate these entities employing immunohistochemical (IHC) studies (some of which we review here), to date, no panel of IHC stains exists, to our knowledge, to distinguish these entities. To devise a panel of IHC stains to distinguish CMBC from SGC. Twelve cases of ductal CMBCs (11 not otherwise specified type, and 1 basal phenotype), 11 cases of SGCs (5 eccrine carcinomas, 3 porocarcinomas, and 3 microcystic adnexal carcinomas), 2 benign sweat gland neoplasm cases, and 2 primary breast cancer cases were retrieved and analyzed with the following IHC panel: mammaglobin, gross cystic disease fluid protein (GCDFP) 15, p63, basal cytokeratins (CK5, CK14, and CK17), androgen receptor, and PAX5. The p63 was only weakly expressed in 1 of 12 CMBC cases (8.3%), whereas it was strongly expressed in 10 of 11 SGC cases (90.9%) (P < .001). Basal cytokeratins demonstrated a similar immunoprofile in the SGC group, with 10 of 11 cases (90.9%) expressing all 3 markers, and a variable immunoprofile in the CMBC group with 0% (CK14) (P < .001) to 16.7% (2 of 12 cases; CK5 and CK17) (P < .001) expression. Mammaglobin was expressed in 8 of 12 cases (66.7%) of CMBC. Together, these 5 IHC stains were combined to make a panel that was 100% sensitive and 91% specific in distinguishing between CMBC and SGC.

Annular erythemas diagnosed as cutaneous metastasis of breast carcinoma: spontaneous resolution of the lesions

Annular erythemas diagnosed as cutaneous metastasis of breast carcinoma: spontaneous resolution of the lesions

Carcinome apocrine cutané axillaire inhabituel : difficultés diagnostiques histologiques

Apocrine carcinoma of the skin (ACS) is a rare adnexal neoplasm presenting as an indurated slow-growing dermal or subcutaneous plaque that often occurs in the axilla. Histological distinction between ACS and cutaneous metastases of breast carcinoma may be difficult. A 64-year-old man presented with a slowly growing left axillary mass, which he had noticed for 2 years, without any other functional or clinical symptoms. Histological examination of the skin biopsy showed dermal invasion with atypical cells in an "Indian file" pattern. The pattern of the tumour and immunohistochemical staining suggested a diagnosis of breast carcinoma metastasis. However, the history of a slow-growing tumour and negative initial testing for a primary adenocarcinoma supported the hypothesis of ACS. A 100 cases of ACS have been reported in the literature with the main site being the axillary area. The differential diagnostic between axillary ACS and metastasis of lobular breast carcinoma has been discussed recently. Diagnosis may be difficult since the pattern of the tumour can be misleading and immunomarkers are not always specific. We report a new case of axillary ACS histologically mimicking lobular breast carcinoma metastasis.

Cutaneous metastases of breast carcinoma: a case report

BackgroundCutaneous metastases can have variable clinical appearances and can mimic benign skin lesions. They are usually seen in patients with advanced disease, but they can be the presenting lesion.Case presentationA 48-year-old woman presented with a 3-month history of progressive appearance of multiple asymptomatic nodular lesions on the chest. The recognition of cutaneous metastases often dramatically alters therapeutic plans, especially when metastases signify persistence of cancer originally thought to be cured. The most common tumor to metastasize to the skin is breast cancer.ConclusionEvery practitioner should be highly suspicious of acute-onset, persistent, firm papulonodules, especially when they develop on the chest.

Carcinoma erysipeloides of the breast: two case reports

AbstractCarcinoma erysipeloides (CE) is an uncommon cutaneous metastasis of breast carcinoma; it may be confused with erysipelas and other inflammatory lymphedemas. We report two cases of CE in women previously treated by mastectomy for ductal invasive carcinoma, CE is the clinical manifestation of dissemination of neoplastic cells in the cutaneous lymphatic vessels: thus it has a very poor prognosis despite all therapies.

Carcinoma erysipeloides of the breast: two case reports

Carcinoma erysipeloides (CE) is an uncommon cutaneous metastasis of breast carcinoma; it may be confused with erysipelas and other inflammatory lymphedemas. We report two cases of CE in women previously treated by mastectomy for ductal invasive carcinoma. CE is the clinical manifestation of dissemination of neoplastic cells in the cutaneous lymphatic vessels; thus it has a very poor prognosis despite all therapies.

An evaluation of photodynamic therapy in the management of cutaneous metastases of breast cancer

A series of 37 patients with cutaneous metastases of breast carcinoma were treated with photodynamic therapy (PDT) to the chest wall; decreasing doses of photofrin II and increasing light doses were used in order to test drug/light dose reciprocity and determine the lowest effective dose of photofrin II. 5 patients (13.5%) achieved a complete response, 13 (35.1%) demonstrated partial responses and 19 (51.4%) showed no benefit. The extent and type of recurrent disease were strong determinants of the likelihood of response. Minimal and nodular disease responded well to PDT ( 5 5 complete responses); partial responses were seen in 11 20 (55%) of patients with disease of moderate extent. No patient with extensive erythema derived any benefit ( 0 5 ), and only 2 12 (17%) patients with advanced nodularity showed a partial response. Reductions in photofrin dose to 0.75 mg/kg with reciprocal increases in light dose to 182 J/cm 2 did not impair treatment efficacy.